Table 4. Genotypic Resistance at Failure in ACTG 368 (n=80).
| Drug / Class | Resistance Pattern | ABC+IDV+EFV a (n=36) |
IDV+EFV b (n=44) |
Total (n=80) |
|---|---|---|---|---|
| nRTI | NAMsa alone | 2 (6%) | 8 (18%) | 10 (13%) |
| NAMs + M184V | 18 (50%) | 14 (32%) | 32 (40%) | |
| NAMs + T69D or L74V | 2 (6%) | 2 (5%) | 4 (5%) | |
| NAMs + 184V+69D or 74V | 0 | 2 (5%) | 2(3%) | |
| M184V alone | 9 (25%) | 5 (11%) | 14 (17%) | |
| T69D or L74V alone | 0 (0%) | 2 (5%) | 2 (3%) | |
| Q151M complexb | 1 (%) | 2 (%) | 3 (4%) | |
| No nRTI resistance | 4 (%) | 9 (%) | 13 (16%) | |
| NNRTI | K103N (alone) | 12 (33%) | 17 (39%) | 29 (36%) |
| K103N + V108I | 2 (6%) | 2 (5%) | 4 (5%) | |
| K103N + P225H | 1 (3%) | 1 (2%) | 2 (3%) | |
| K103N+Y188L | 1 (3%) | 0 (0%) | 1 (1%) | |
| K103N+L100I | 2 (6%) | 6 (14%) | 8 (10%)# | |
| K103N+G190A/S | 1 (3%)** | 3 (7%)ˆ | 4 (5%) | |
| Y181C | 1 (3%) | 0 (0%) | 1 (1%) | |
| G190A/S | 1 (3%)*** | 2 (5%)ˆˆ | 3 (4%) | |
| L100I+G190A/S | 0 | 1 (2%)** | 1 (1%) | |
| K103N+V108I+P225H | 1 (3%) | 0 (0%) | 1 (1%) | |
| No NNRTI resistance | 14 (39%) | 12 (27%) | 26 (33%) | |
| IDV | Primary Mutationsc | 0 (0%) | 3 (7%) | 3 (4%) |
| Secondary Mutationsd | ||||
| 0 | 20 (56%) | 16 (36%) | 36 (45%) | |
| 1 | 9 (25%) | 23 (52%) | 32 (40%) | |
| 2 | 6 (17%) | 2 (5%) | 8 (10%) | |
| 3 | 1 (3%) | 1 (2%) | 2 (3%) | |
| 4 | 0 (0%) | 2 (5%) | 2 (3%) |
NAMs include any one of the following reverse transcriptase mutations: M41L, E44D, D67N, K70R, V118I, L210W, T215Y/F, K219E/Q.
Q151M complex is defined as the presence of one or more of the following reverse transcriptase mutations: A62V, V75I, F77L, F116Y, Q151M.
Primary or major IDV resistance mutations are defined as one or more of the following protease mutations: M46I/L, V82A/F/T, I84V.
Secondary or minor IDV resistance mutations are defined as one or more of the following protease mutations: L10I/R/V, K20M/R, L24I, V32I, M36I, I54V, A71V/T, G73S/A, V77I, L90M.
G190A
G190S
2 G190A, 1 G190S
1 G190A, 1 G190S
5/8 of these samples also acquired the L74V muatation. 4/5 of these samples were from subjects assigned to the EFV+IDV arm. L74V was present at failure only in samples that also had the K103N and L100I mutations, and was not present in any of the baseline samples of the 4 subjects with L74V at failure, who had genotypic testing at baseline.